Although dissolution cannot be used as a predictor of therapeutic efficiency; it can be used as a qualitative and a quantitative tool, which can provide important information about biological availability of a drug as well as batch-to-batch consistency [13]. In the cases when the in-vitro results fail to predict the in-vivo performance of a drug product, larger clinical studies are needed
to assess the product bioavailability, thus additional cost will be added to the drug development expenses [11]. Therefore, dissolution is considered one of the most important quality control tests performed on pharmaceutical dosage forms and validation of dissolution methods and is an important part of good manufacturing practice [12]. With modern Y-27632 in vitro technology and advancement in research of drug delivery
and more emphasis on in-vivo predictability of therapeutic effect by means of in-vitro test, dissolution tests have been gaining more and more popularity [14]. Whenever a new solid dosage form is developed or produced, it is necessary to ensure that drug dissolution occurs in an appropriate manner. The ultimate aim of performing dissolution tests is to predict the extent release and absorption of the administered drug in-vivo, i.e. in-vitro–in-vivo correlation. However, extended release performance obtained in-vitro does not necessarily mean that the buy TSA HDAC formulation will perform similarly in-vivo [14]. The pharmacological activity of a drug can be evaluated by assessing its dissolution behaviour. Therefore, in-vitro–in-vivo correlation (IVIVC), which is a direct relationship between bioavailability 3-oxoacyl-(acyl-carrier-protein) reductase of a drug and its in-vitro dissolution rate is demonstrated. Drug absorption from solid dosage form following oral administration depends on the stages disintegration, disaggregation, drug release from
the pharmaceutical form, its dissolution under physiological conditions and the permeability through the biological membranes [15]. These considerations indicate that an in-vitro dissolution test is a very important stage to predict the drug in-vivo performance. The bioavailability, which describes the rate and extent of the active drug that is absorbed, may be altered by any factor that changes the disintegration and dissolution drug process [15]. For a new compound, dissolution testing is performed mainly to evaluate the stability of formulations, rate of drug release, monitor product consistency and establish in-vitro–in-vivo correlations [16]. This type of correlation would match changes in the in-vitro dissolution rate to meaningful in-vivo product performance quality. To utilise the dissolution test as a surrogate for bioequivalence, IVIVC must be predictive of in-vivo performance of the drug [9].